Novel immunotherapy strategies and biomarker discoveries continue to reshape oncology. Pfizer's Padcev combined with Merck’s Keytruda extends survival in muscle-invasive bladder cancer patients ineligible for chemotherapy, prompting regulatory discussions to expand indications. Researchers identified EPIC1 lncRNA as a driver of triple-negative breast cancer immunotherapy resistance, offering a target to boost treatment efficacy. A cancer vaccine against KRAS mutations also elicited promising immune responses in pancreatic and colorectal cancer cohorts. Machine learning platforms like Molecular Twin integrate multiomic data to unlock new predictive biomarkers, potentially enhancing patient stratification and therapeutic outcomes.